Catalyst Event
SK Biopharmaceuticals Co Ltd (326030) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
3/26/2026, 12:00:00 AM
Announcement of a 44.28 billion KRW drug supply contract with U.S. subsidiary SK Life Science, Inc. for the sale of Cenobamate (Xcopri) scheduled. Low importance is estimated as it is an internal transaction with limited market impact.
Korean Translation
미국 자회사 SK Life Science, Inc.와 442.8억원 규모의 세노바메이트(엑스코프리) 공급 계약 체결 예정됨. 내부거래로 인한 주가 영향 제한을 고려하여 Low로 분류하며 2026-03-26 진행 예정됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Earnings Release
Q1 2026 earnings release for April 29, 2026 scheduled. Minimal market impact from the date announcement expected.
4/29/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
An investor relations (IR) meeting to announce the group's integrated strategy and the progress of major pipelines; low impact anticipated as it is a routine communication event, scheduled.
4/9/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Cancellation of 9.11 million treasury shares, valued at approximately KRW 1.71 trillion, effective April 1, 2026. This largest-ever cancellation is expected to have a high market impact.
4/1/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
The 82nd Annual General Meeting of Shareholders on 2026-03-30 is a routine meeting with low expected price impact scheduled.
3/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Other
The ex-dividend date for the 2025 final dividend of 1,100 KRW per common share is scheduled for 2026-03-30; market impact is estimated to be low (>=1%) following typical dividend adjustments, scheduled.
3/30/2026, 12:00:00 AM